• Home
  • About
  • Drug Development Pipeline
  • News
  • Investors
  • Careers
  • Contact
  • TSX.V: RKV
  • FSE: 7JO0
  • OTCMKTS: RKVTF

Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement

by Rakovina Therapeutics | Mar 12, 2026 | Uncategorized

DOWNLOAD VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that the TSXV...

Rakovina Therapeutics Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements

by Rakovina Therapeutics | Mar 10, 2026 | Uncategorized

DOWNLOAD VANCOUVER, British Columbia, March 5, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce closing of its...

Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million

by Rakovina Therapeutics | Feb 23, 2026 | Uncategorized

DOWNLOAD Proposed $1.0 Million Convertible Debenture and Warrant Financing andConcurrent Common Share Private Placement Up to $1.0 MillionIntended to Support Near-Term Operations Vancouver, British Columbia – February 20, 2026 – Rakovina Therapeutics Inc. (TSX-V:...

Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit

by Rakovina Therapeutics | Feb 4, 2026 | Uncategorized

DOWNLOAD Highlights: Strategic Validation: Industry feedback confirms Rakovina’s approach targeting PTEN-deficient tumours with brain-penetrant ATR/mTOR inhibitors addresses critical gaps left by recent late-stage clinical setbacks in the field. Expanded Opportunity:...

Rakovina Therapeutics Announces Corporate Update Including up to $1.6 Million in New Financing, Leadership Appointments and Debt Restructuring

by Rakovina Therapeutics | Jan 28, 2026 | Uncategorized

Proposed $1.0 million Convertible Debenture and concurrent $600,000 Private Placement Intended to Support Near-Term Operations Board and Management Enhancements Strengthen Governance and Capital Markets ExecutionCurrent Convertible Debenture Maturity Extended; Further...
« Older Entries
Next Entries »

Suite 720, 999 West Broadway, Vancouver, British Columbia
Canada V5Z 1K5

Home

About

Drug Development Pipeline

News

Investors

Careers

Contact

Company Disclosure

Privacy Policy

Subscribe

To Receive Company Updates

Copyright ©2020-2026 Rakovina Therapeutics Inc. All rights reserved.  | Privacy Policy | Terms of Use |  Site by Vanooms Media